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A. Ålgars9, A. Lamminmäki10, P. Halonen6, R. Ristamäki9, J. Räsänen11, H. Karjula 12, Y. Vaalavuo13, M. Lavonius14 and
P. Osterlund6,8
1Department of Transplantation and Liver Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
2Department of Radiology, Helsinki University Hospital, Päijät-Häme Central Hospital, Lahti, Finland
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Abstract
Background: Metastasectomy is probably underused in metastatic colorectal cancer. The aim of this study was to investigate the
effect of centralized repeated assessment on resectability rate of liver metastases.
Methods: The prospective RAXO study was a nationwide study in Finland. Patients with treatable metastatic colorectal cancer at any
site were eligible. This planned substudy included patients with baseline liver metastases between 2012 and 2018. Resectability was
reassessed by the multidisciplinary team at Helsinki tertiary referral centre upfront and twice during first-line systemic therapy.
Outcomes were resectability rates, management changes, and survival.
Results: Of 812 patients included, 301 (37.1 per cent) had liver-only metastases. Of these, tumours were categorized as upfront resect-
able in 161 (53.5 per cent), and became amenable to surgery during systemic treatment in 63 (20.9 per cent). Some 207 patients
(68.7 per cent) eventually underwent liver resection or ablation. At baseline, a discrepancy in resectability between central and local
judgement was noted for 102 patients (33.9 per cent). Median disease-free survival (DFS) after first resection was 20 months and over-
all survival (OS) 79 months. Median OS after diagnosis of metastatic colorectal cancer was 80, 32, and 21 months in R0–1 resection,
R2/ablation, and non-resected groups, and 5-year OS rates were 68, 37, and 9 per cent, respectively. Liver and extrahepatic metastases
were present in 511 patients. Of these, tumours in 72 patients (14.1 per cent) were categorized as upfront resectable, and 53 patients
(10.4 per cent) became eligible for surgery. Eventually 110 patients (21.5 per cent) underwent liver resection or ablation. At baseline,
a discrepancy between local and central resectability was noted for 116 patients (22.7 per cent). Median DFS from first resection was
7 months and median OS 55 months. Median OS after diagnosis of metastatic colorectal cancer was 79, 42, and 17 months in R0–1
resection, R2/ablation, and non-resected groups, with 5-year OS rates of 65, 39, and 2 per cent, respectively.
Conclusion: Repeated centralized resectability assessment in patients with colorectal liver metastases improved resection and
survival rates.
Introduction
Hepatic resection is considered potentially curative for patients
with colorectal liver metastases (CRLMs), with 5-year overall
survival (OS) rates of 30–50 per cent1. Resectability rates have
been increasing as a result of improved surgical techniques and
conversion therapy with chemotherapy and targeted agents2–6.
There is a strong correlation between response to treatment and
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resection rate4. In studies that enrolled selected patients with
liver-only metastases, 24–54 per cent of patients underwent tu-
mour resection after systemic therapy, compared with 1–26 per
cent of patients in studies that included unselected patients with
CRLMs4.
Resectability can also be improved by interventional methods,
such as local ablative therapy (LAT)7–9. Technical resectability
has become a reality in more demanding surgery for liver metas-
tases. Good results have been shown even in patients with 10 or
more liver metastases, with two-stage hepatectomy for bilobar
metastases and after second-line conversion therapy10–12.
Resectability is generally defined based on the ability to
remove all metastases with clear margins while maintaining
sufficient future liver remnant. If extrahepatic metastases are
present, all sites should be amenable to curative treatment.
The decision regarding liver resectability is easy if only a few
small metastases are present without involvement of crucial
structures, such as central vessels or bile ducts, or if the liver
is full of metastases, but borderline resectable disease is more
challenging.
Multidisciplinary teams (MDTs) are increasingly being
engaged in assessment and improvement of resectability13.
Decisions between palliative care or treatment with curative in-
tent can be difficult, and opinions may differ, depending on the
experience and expertise of the MDT. A study2 assessing border-
line resectability revealed great variability in views on resectabil-
ity among liver surgeons both upfront and after conversion
therapy. A recent study14 showed significant variation in opinions
between specialties, with frequent underestimation of resectabil-
ity by medical oncologists and non-hepatobiliary surgeons.
The hypothesis is that resection is probably underused in
real-world oncology practice. The aim of this study was to assess
real-world resectability and conversion rates and survival in
patients fit for oncological treatment of CRLMs with centralized
repeated assessment.
Methods
This was a planned substudy of patients with baseline liver metas-
tases with or without extrahepatic metastatic sites, from the pro-
spective nationwide investigator-initiated RAXO study
(NCT01531621, EudraCT2011-003158-24). Treatable patients, de-
fined as those with metastatic colorectal cancer fit for oncological
treatment, referred to oncology units were recruited. Inclusion cri-
teria were: histologically confirmed colorectal cancer with liver me-
tastases at baseline; patient scheduled for first-line systemic
therapy; age over 18 years; and signed written informed consent
obtained according to Good Clinical Practice (GCP). The ethics com-
mittee at Helsinki University Hospital (242/13/03/02/2011) and each
hospital approved the study. The primary objective was to assess
the overall resectability and conversion of metastases, and out-
comes after resection. The protocol is available from the authors on
request.
Protocol for assessing resectability
CRLMs were considered resectable if complete resection with
tumour-free margins was feasible, and at least 30 per cent of liver
volume would be preserved, including at least two Couinaud’s
segments with adequate vascular inflow and outflow and biliary
drainage. All sites should be resectable in patients with extrahe-
patic metastases. All metastatic sites were recorded from base-
line until death or end of follow-up, and potential resectability
was assessed.
Resectability was recorded prospectively and centralized at
Helsinki University Hospital, which is a tertiary liver centre per-
forming over 200 liver resections and 60–70 liver transplant annu-
ally. The oncologist submitted information on the primary tumour,
TNM stage, metastatic sites, and dates of primary diagnosis and
metastatic colorectal cancer to a secure online database (https://
www.raxo.fi) (Fig. S1). All available imaging studies were provided to
the tertiary centre for a second opinion. The MDT consisted of expe-
rienced liver surgeons, abdominal radiologists, and other special-
ists, such as gastrointestinal surgeons, thoracic surgeons,
cytoreductive surgeons, gynaecologists, thoracic radiologists, and
PET–CT specialists as needed. The resectability of liver and other
metastases was assessed at time of diagnosis of metastatic colorec-
tal cancer, and at the first and second response evaluation (at 8–10-
week intervals) during first-line therapy.
Local assessment of baseline resectability outside the tertiary
referral centre was recorded as upfront resectable with or with-
out neoadjuvant therapy, borderline starting conversion therapy,
or non-resectable.
Imaging
CT of the chest, abdomen, and pelvis was used to image metasta-
ses. MRI was added in hepatic steatosis or if CT was not unequiv-
ocal. [18F]fluorodeoxyglucose PET–CT was used in selected
patients to evaluate the extrahepatic spread if CT was not con-
clusive or there was a clinical discrepancy.
Guidelines for CT protocols were standardized in all hospitals.
Patients underwent scanning with 64-/128-slice CT after adminis-
tration of low-osmolarity non-ionic contrast (iodine concentra-
tion 350 mg/ml at 3 ml/s). Baseline CT included the chest and
upper abdomen in the late arterial phase, and the abdomen and
pelvis in the portal venous phase. Follow-up CT was performed
during the portal venous phase. CT images were reconstructed
with 3-mm slices.
Second opinion on resectability
The second opinion was provided online to the database (https://
www.raxo.fi) using a structured form on which number of
CRLMs, size of the largest lesion, location (unilobar/bilobar), and
affected liver segments were recorded (Fig. S2). The statement of
resectability included three options: resectable, borderline resect-
able but possibly convertible, and non-resectable. The five rea-
sons for non-resectability were location, number of metastases
(denoted as 15, if more than 15), size of the largest lesion, non-
treatable extrahepatic spread, or other. Interventions, such as
resections and/or LAT, were performed according to clinical prac-
tice; liver resections were undertaken at six centres, with referral
of those requiring demanding procedures to the tertiary unit.
The lungs were always assessed also. Number and size of metas-
tases, and involved lobes were recorded, and denoted as resectable
or non-resectable. Thoracic surgeons were consulted as needed.
Other extrahepatic metastases were noted as resectable or not.
Helsinki tertiary centre and the five other hospitals perform-
ing liver resections retrospectively compared their CRLM resec-
tion rates during the prospective study period from 2012 to 2018,
with the preceding period from 2005 to 2011. The Helsinki tertiary
centre is responsible for liver MDTs and resections in the Helsinki
University region and for seven other regional hospitals. The
most demanding liver surgery (such as 2-stage procedures, most
major hepatectomies) from any part of Finland is centralized to
Helsinki according to state regulation. Finland is divided into five
university hospital catchment areas and the resection rate per
million population was compared between these areas.
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Systemic therapy
Each hospital used its own standard treatment protocols based
on National Comprehensive Cancer Network and European
Society for Medical Oncology guidelines. Systemic therapy was
given until disease progression or toxicity occurred, or resectabil-
ity had been achieved. For upfront resectable metastatic disease,
perioperative oxaliplatin-based treatment was preferred15. In the
conversion setting, the most intensive regimen that could be
Table 1 Demographics and baseline characteristics of patients with metastatic colorectal cancer with liver-only disease or liver
metastases and extrahepatic sites
Liver-only metastases
(n 5 301)
Liver and extrahepatic metastases
(n 5 511)
Demographics
Age (years)* 66 (26–87) 66 (24–90)
 70 202 (67.1) 345 (67.5)
 70 99 (32.9) 166 (32.5)
Sex M 196 (65.1) 316 (61.8)
F 105 (34.9) 195 (38.2)
ECOG perormance status 0 112 (37.2) 107 (20.9)
1 154 (51.2) 286 (56.0)
2–3 35 (11.6) 118 (23.1)
Primary tumour
Location Right colon 79 (26.2) 140 (27.4)
Left colon 154 (51.2) 168 (32.9)
Rectum 67 (22.3) 201 (39.3)
Multiple 1 (0.3) 2 (0.3)
Surgery
Upfront or simultaneous 301 (100) 203 (39.7)
After neoadjuvant therapy/conversion 0 (0) 92 (18.0)
Primary not operated 0 (0) 216 (42.3)
Metastases
Presentation
Synchronous 178 (59.1) 436 (85.3)
Metachronous 123 (40.9) 75 (14.7)
No. of sites 1 301 (100) 0 (0)
2 0 (0) 254 (49.7)
3–6 0 (0) 257 (50.3)
Liver Bilateral 148 (49.2) 380 (74.4)
Unilateral 153 (50.8) 131 (25.6)
No. of lesions* 2 (1–15†) 6 (1–15†)
 15 lesions 35 (11.6) 183 (35.8)
Largest lesion (mm)* 28 (5–190) 40 (5–200)
Lung Baseline 0 (0) 218 (42.7)
During follow-up 107 (35.5) 313 (61.3)
Peritoneal Baseline 0 (0) 72 (14.1)
During follow-up 36 (12.0) 127 (24.9)
Lymph nodes Baseline 0 (0) 173 (33.9)
During follow-up 75 (24.9) 249 (48.7)
Patients who had R0–2 resection/LAT n¼ 207 n¼ 110
Interventions
Liver‡ Major resection 99 50
Minor resection 125 68
LAT 41 16
Lung Resection 23 40
Local relapse Surgery 5 15
Gynaecological/urological Resection 3 11
Peritoneal Cytoreductive 6 HIPEC 7 8
Lymph nodes Lymphadenectomy 4 3
Skin/intramuscular Excision 1 5
Systemic therapy§
No. of lines 1 133 (44.2) 187 (36.6)
2 74 (24.6) 125 (24.5)
 3 94 (31.2) 199 (38.9)
Chemotherapy Fluoropyrimidine 289 (96.0) 490 (95.9)
Oxaliplatin 194 (64.5) 307 (60.1)
Irinotecan 80 (26.6) 132 (25.8)
VEGF inhibitor Bevacizumab 144 (47.8) 310 (60.7)
Aflibercept 3 (1.0) 3 (0.6)
EGFR inhibitor Panitumumab 38 (12.6) 50 (9.8)
Cetuximab 22 (7.3) 23 (4.5)
Values in parentheses are percentages unless indicated otherwise; * values are median (range). † Maximum number recorded was 15, even if more liver metastases
were present. ‡ Total number of interventions (re-resections included); median 2 (range 1–10) per patient. § Maximum during all lines of therapy. ECOG, Eastern
Cooperative Oncology Group; LAT, local ablative therapy; HIPEC, hyperthermic intraperitoneal chemotherapy; VEGF, vascular endothelial growth factor; EGFR,
epidermal growth factor receptor.
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tolerated was used, usually a doublet or triplet chemotherapy
regimen combined with targeted agents, such as bevacizumab,
cetuximab, or panitumumab, according to RAS/BRAF status
and sidedness7. The recommendation was to continue the
same chemotherapy for 3 months after resection at the physi-
cian’s discretion. Targeted agents were not generally used in the
adjuvant setting after publication of negative cetuximab and
bevacizumab findings16–18. Treatment with bevacizumab was
stopped 5–6 weeks before surgical intervention. One additional
cycle of chemotherapy was subsequently administered before
surgical exploration if tolerated by the patient. Chemotherapy
was restarted 4 weeks after surgery in the adjuvant setting if
there were no complications that delayed its initiation.
Follow-up
Patients were followed after resection according to the study pro-
tocol. First imaging with CT of the chest, abdomen, and pelvis,
laboratory tests including tumour markers (carcinoembryonic
antigen with or without carbohydrate antigen 19-9), and clinical
evaluation were done 2–3 months after resection. Thereafter,
patients were followed at 3-month intervals to 2 years and at 6-
month intervals up to 5 years. Response evaluation was per-
formed every 2–3 months for patients receiving systemic treat-
ment.
Statistical analysis
The main objectives according to the protocol were to analyse re-
sectability, conversion, and median disease-free survival (DFS),
progression-free survival (PFS), and OS. Survival was assessed by
Kaplan–Meier survival analysis with log rank test, and Cox
multivariable regression analysis. The cut-off date for survival
status was 7 February 2020. Median OS was calculated from first
intervention (resection or LAT) to death from any cause or cen-
sored at last follow-up. DFS was calculated from first interven-
tion to relapse of metastatic colorectal cancer, death from any
cause, or censored at last date of follow-up. PFS was calculated
from metastatic colorectal cancer diagnosis to progression on
systemic therapy, relapse after intervention, death from any
cause, or censored at the last date of follow-up. OS after diagno-
sis of metastatic colorectal cancer was calculated until any cause
of death or censoring at last follow-up. Two-sided P < 0.050 was
considered statistically significant.
A sample size calculation was performed. To detect a hazard
ratio (HR) for death of 0.70 in the resected and/or ablated group
compared with the no-resection group treated with first-line
systemic therapy, with a two-sided type I error of 0.05 and type II
error of 0.20, 671 patients were needed, assuming median OS of
2 years in the no-resection group19. A 5-year accrual period was
planned, with assumed 1 per cent loss to survival follow-up.
Based on a presumed treatment allocation of 25 per cent resected
or ablated and 75 per cent treated with systemic therapy,
329 deaths were targeted for the final OS analysis.
Results
Between June 2012 and October 2018, a total of 1086 patients with
metastatic colorectal cancer at all 21 oncology units in Finland
were included (The RAXO study group is presented in Appendix
S1). Some 812 patients with colorectal cancer and liver metastases




n = 301 (37.1%)
Resectable
n = 161 (53.5%)
R0–1 resection
n = 56 (89%)
R0–1 resection
n = 29 (55%)
R2 resection n = 2 (3%)
LAT n = 4 (6%)
No procedure
n = 0 (0%)
No procedure n = 15
   PD n = 11 (15%)
   Co-morbidity n = 4 (6%)
R2 resection n = 16 (22%)
Resection + LAT n = 1 (1%)
R2 resection n = 22 (42%)
Resection + LAT n = 2 (4%)
R2 resection n = 1 (0.7%)
LAT n = 8 (5.0%)
No procedure n = 16
   palliative n = 2 (1.2%)
   PD n = 10 (6.2%)
   Co-morbidity n = 4 (2.5%)
No procedure n = 1
   PD n = 1 (2%)
R0–1 resection
n = 136 (84.5%)
R0–1 resection
n = 40 (56%)
Resectable
n = 72 (14.1%)
Converted
n = 53 (10.4%)
Converted
n = 63 (20.9%)
Unconvertible n = 8 (2.7%)
Non-resectable
n = 69 (22.9%)
Unconvertible n = 18 (3.5%)
Non-resectable
n = 368 (72.0%)
Liver & extrahepatic
n = 511 (62.9%)
Fig. 1 Study flow chart
PD ¼ progressive disease
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were enrolled in this planned substudy, of whom 301 had meta-
static colorectal cancer limited to the liver, and 511 had liver and
extrahepatic metastases. Consent was obtained from approxi-
mately 40 per cent of eligible patients nationwide; the enrolment
rate was 58 per cent at the five university hospitals and two larg-
est regional hospitals with dedicated study personnel available,
and 31 per cent at smaller regional hospitals where local oncolo-
gists did all study procedures. At inclusion, all patients were eligi-
ble for chemotherapy, but 20 (2 per cent) eventually received best
supportive care only and were included in the systemic therapy
group according to the intention-to-treat principle. At the data
cut-off point, 71 per cent of patients had died. Median follow-up
was 59 (range 17–88) months. Patient characteristics in the two
groups are shown in Table 1.
Resectability and resection rates
Patients with liver-only metastatic colorectal cancer
At first central resectability evaluation, 161 of 301 patients with
liver-only metastatic colorectal cancer (53.5 per cent) were con-
sidered to have upfront resectable tumours, whereas 71 (23.6 per
cent) had borderline, and 69 (22.9 per cent) had non-resectable
disease (Fig. 1). A discrepancy was noted between central and
local resectability assessment at baseline in 102 patients
(33.9 per cent) (Fig. 2). Local underestimation of resectability
of tumours categorized centrally as resectable or borderline re-
sectable was seen for 37.3 and 11.3 per cent of patients respec-
tively. Local overestimation was observed in 22.5 and 26.1 per
cent of patients considered to have borderline or unresectable
disease at central re-evaluation. In the repeated resectability
evaluation during conversion therapy, disease in 63 patients was
converted (60 of 71 borderline and 3 of 69 non-resectable) (Fig. 1).
Of the 161 patients with disease that was resectable upfront,
145 (90.1 per cent) had an intervention (R0–1 resection, R2 resec-
tion or LAT) and 16 did not undergo tumour resection or ablation
(Fig. 1). In total, a liver intervention was undertaken in 207 of 301
patients (68.8 per cent) and was curative in 192 (63.8 per cent).
Tumour burden, new metastatic sites, and interventions are
detailed in Table 1 and Table S1. The liver or LAT rate was 41 (19.8
per cent) and median time to re-resection was 16 (95 per cent c.i.
11 to 21) months. Neoadjuvant, conversion, and/or adjuvant
therapy was given to 94 and 63 per cent in conjunction with first
and second resection respectively (Table S1).
Patients with concomitant liver and extrahepatic
metastases
Extrahepatic metastases were present at 17 sites, most common
pulmonary metastases, then distant lymph node metastases,























































b   Liver + extrahepatic metastases
Fig. 2 Rates of patients with upfront resectable, borderline, and non-resectable disease in central assessment compared local assessment
a Liver-only and b liver and extrahepatic metastases.
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ovarian, skin/subcutaneous, and/or brain metastases (Table 1).
At first central resectability evaluation, 72 patients with liver and
extrahepatic metastases (14.1 per cent) were considered to have
resectable, 71 (13.9 per cent) borderline resectable, and 368 (72.0
per cent) non-resectable lesions (Fig. 2). A discrepancy was noted
between baseline central and local resectability assessment in
116 of the 511 patients (22.7 per cent) (Fig. 2). Local underestima-
tion of resectability for tumours categorized centrally as resect-
able or borderline was seen in 59.7 and 33.8 per cent of patients
respectively. Local overestimation was noted in 11.3 and 11.1 per
cent of patients who were considered centrally to have borderline
resectable or unresectable disease respectively. On repeated eval-
uation during conversion therapy, tumours in 53 patients became
eligible for surgery (Fig. 1).
Of 125 patients with tumours categorized as resectable either
upfront or after conversion therapy, resection or ablation was
performed in 110 (88.0 per cent), of whom 69 (55.2 per cent)
underwent curative R0–1 resection (Fig. 1). Non-curative resec-
tions were more common among patients in the converted group
(42 per cent) than in upfront resectable group (22 per cent)
(Fig. 1), and were mostly due to progressive disease before
second-site operation. Tumour burden, metastatic sites, and
interventions are shown in Table 1 and Table S1. Liver re-resection
was performed in 18 patients (16.4 per cent) and median time to
re-resection was 10 (95 per cent c.i. 9 to 12) months.
Neoadjuvant, conversion, and/or adjuvant therapy was given to
91 and 73 per cent in conjunction with first and second resection
(Table S1).
Comparison of resection numbers between two periods
The total number of CRLM resections at Helsinki tertiary centre
(1.67 million inhabitants) increased from 260 in 2005–2011 to 472
during the study period (2012–2018), an 81.5 per cent increase. At
seven referring hospitals (1.30 million inhabitants), the number
of CRLM resections increased from 77 to 154 (100 per cent in-
crease). In the five other hospitals performing liver resections
(serving an area of 2.53 million inhabitants), numbers increased
from 197 to 365 (85.3 per cent increase).
Comparison of resection rates in RAXO trial between
university hospital catchment areas
The CRLM resection rate in the RAXO study was 144 per million
population for Helsinki tertiary centre and 81–112 per million in
the four other university regions. There were no differences in
median OS after diagnosis of metastatic colorectal cancer among
patients who underwent R0–1 resection between the five univer-
sity catchment areas (HR 0.98, 95 per cent c.i. 0.85 to 1.13).
Overall, disease-free, and progression-free
survival
Liver-only metastatic colorectal cancer
Median OS after the first resection or ablation in patients with
liver-only metastatic colorectal cancer was 79 (95 per cent c.i.
63 to 96) months, and 3- and 5-year OS rates were 76 and 63 per
cent respectively (Fig. 3a). Median DFS was 20 (11 to 30) months)
(Fig. 3b).
Median OS after diagnosis of metastatic colorectal cancer in
the R0–1 resection, R2/ LAT, and systemic therapy groups was (95
per cent c.i. 71–90), 32 (11 to 53), and 21 (17 to 24) months, with 5-
year OS rates of 68, 37, and 9 per cent, respectively (Fig. 4a). OS
calculated by the 12-month landmark method to control for
guarantee-time bias is shown in Fig. S3. Median PFS was 34 (25 to
43), 14 (12 to 17), and 9 (7 to 11) months in the R0–R1 resection,
R2/LAT, and systemic treatment groups respectively (Fig. 4b).
Liver and extrahepatic sites
Median OS after first resection/ablation in the liver and extrahe-
patic metastases group was 55 (95 per cent c.i. 47 to 64) months,
with 3- and 5-year OS rates of 66 and 45 per cent respectively
(Fig. 3a). Median DFS was 7 (4 to 9) months (Fig. 3b).
Median OS after diagnosis of metastatic colorectal cancer was
79 (61 to 97), 42 (17 to 57), and 17 (15 to 19) months in the R0–1 re-
section, R2/LAT, and systemic treatment groups, with 5-year OS
rates of 65, 39, and 2 per cent, respectively (Fig. 4c and Fig. S3).
Median PFS was 24 (18 to 31), 16 (10 to 21), and 9 (8 to 10) months
respectively (Fig. 4d).
Survival for all patients undergoing resection either upfront or after
conversion
OS after first resection among all patients who had curative
resection did not differ between upfront resectable and converted
subgroups (median 76 (95 per cent c.i. 71 to 80) months versus not
reached) (Fig. 5). In the R2/LAT group, no difference was observed
between upfront resected and converted subgroups. Median DFS
was longer in the upfront resectable group than in the converted
group (37 (95 per cent c.i. 22 to 52) versus 25 (11–39) months).
Five-year OS rates increased from 60 per cent for patients in-
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207 124 87 66 47 19
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Fig. 3 Overall and disease-free survival for patients with liver-only
metastases or liver metastases with extrahepatic sites calculated from
the time of first R0–2 resection and/or local ablative therapy
a Overall survival and b Overall survival. a Hazard ratio (HR) 0.66 (95 per cent
c.i. 0.46 to 0.95), P < 0.001; b HR 0.49 (0.38 to 0.65), P < 0.001 (Cox regression).
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2015) to 68 per cent (September 2015 to October 2018) for patients
with any intervention.
Reasons for non-resectability
The main reasons for non-resectability of liver metastases evalu-
ated upfront in 575 patients were: large number of metastases
(192), poorly located metastases (117), size (45), co-morbidity (16),
and non-resectable extrahepatic sites (205). Main reasons why
patients who were considered to have resectable metastases did
not undergo resection included: disease progression during neo-
adjuvant chemotherapy (22), co-morbidity (10), complete re-
sponse to systemic therapy (4), and disease considered
unresectable during surgical exploration (3).
Discussion
This nationwide study showed the benefit of repeated central as-
sessment of resectability of metastatic colorectal cancer. This
pushed the boundaries for resectability, with high resection rates
and encouraging survival. OS may increase significantly with use
of repeated centralized resectability assessment at a tertiary re-
ferral centre.
In this study, the rate of rate of upfront resectability was 53.5
per cent among patients with liver-only metastases and 14.1 per
cent in patients with concomitant extrahepatic disease, whereas
lower rates have been reported in the literature for liver-only me-
tastases6,20–22. The resection/ablation rate after conversion ther-
apy for upfront borderline or non-resectable liver-only
metastases was 45.0 per cent in this study, which is high com-
pared with the 1–26 per cent in unselected population series, and
in line with 24–61 per cent in selected series4,5 and a Dutch phase
III study23 that assessed conversion prospectively. The interven-
tion rate among patients who received conversion therapy was
higher than in earlier studies22,23.
Discrepancy between local and central baseline assessment of
resectability was common, underestimation being more common
than overestimation. This was also observed among experienced
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Fig. 4 Overall survival after diagnosis of metastatic colorectal cancer and Progression free survival
a Overall survival (OS) and b progression free survival (PFS) in patients with liver-only metastases, and c OS and d PFS in patients with liver and extrahepatic
metastases according to treatment strategy. LAT, local ablative therapy; mCRC, metastatic colorectal cancer. a Hazard ratio (HR) 0.15 (95 per cent c.i. 0.10 to 0.21),
P < 0.001 for R0–1; HR 0.70 (0.35 to 1.40), P ¼ 0.304 for R2/LAT; b HR 0.19 (0.14 to 0.26), P < 0.001 for R0–1; HR 0.56 (0.32 to 0.98), P ¼ 0.042 for R2/LAT; c HR 0.12 (0.08
to 0.19), P < 0.001 for R0–1; HR 0.33 (0.22 to 0.50), P < 0.001 for R2/LAT; d HR 0.28 (0.21 to 0.38), P < 0.001 for R0–1; HR 0.52 (0.38 to 0.73), P < 0.001 for R2/LAT; all
versus systemic (log rank test).
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and third assessments on final resectability decisions taken lo-
cally is not available, but local decisions regarding why patients
with resectable metastases or metastases that became resectable
after conversion therapy did not undergo resection were recorded
extensively.
The number of liver resections performed nationwide
significantly increased over time. This is in line with
recent population-based trends for increased liver resec-
tions6,21. Reasons include the effect of repeated central MDT
assessment.
OS after resection or ablation of liver-only metastases was
longer than in other series, for which 5-year survival rates
ranged from 38 to 60 per cent depending on selection crite-
ria1,13,24–26. The 5-year OS rate after liver resection for late meta-
chronous metastases in a previous Finnish20 population-based
study was 67 per cent. Patients with synchronous or early meta-
chronous CRLMs had a reported OS rate of 44–46 per cent20,21.
Patients with extrahepatic disease who underwent resection
or ablation had a longer survival than previously published27,28.
Curative resection was difficult to achieve in this group, but re-
section was still worthwhile. Patients who did not undergo resec-
tion or ablation of liver metastases had a short survival, in line
with previous findings21,22,29. If intervention was curative, sur-
vival was similar between the group of patients who had upfront
resectable metastases and those who underwent liver resection
after downsizing, in line with another study30. The same trend
was noted in patients who underwent R2 resection or ablation.
The strengths of this prospective study include the use of re-
peated assessment of resectability according to the protocol,
thorough recording of all treatments given during a long follow-
up, and no patients lost to follow-up. One major limitation is that
it is not population-based. Nationwide, approximately 40 per
cent enrolment of patients with metastatic colorectal cancer was
achieved, in line with the highest recruiting academic centres,
and clearly higher than the general enrolment rate of less than 5
per cent in clinical studies29. Results are usually given separately
for R0 and R1 resections, but initially structured pathology
reports were not harmonized for metastasectomies at all hospi-
tals. Minimum resection margins were not therefore reported
uniformly.
The practice presented in this study is applicable to diverse
healthcare settings. Patients are not referred for treatment to the
tertiary centre where the MDT recommends whether or not liver
resection should be undertaken, but treated according to local
practice, with the caveat that metastasectomies should be cen-
tralized to hospitals with sufficient organ-specific expertise.
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